Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Deferred Revenue: 2010-2014

Historic Current Deferred Revenue for Anika Therapeutics (ANIK) over the last 5 years, with Dec 2014 value amounting to $24,510.

  • Anika Therapeutics' Current Deferred Revenue was N/A to $52,000 in Q3 2018 from the same period last year, while for Sep 2018 it was $52,000, marking a year-over-year change of. This contributed to the annual value of $24,510 for FY2014, which is 98.90% down from last year.
  • Anika Therapeutics' Current Deferred Revenue amounted to $24,510 in FY2014, which was down 98.90% from $2.2 million recorded in FY2013.
  • Anika Therapeutics' 5-year Current Deferred Revenue high stood at $7.9 million for FY2011, and its period low was $24,510 during FY2014.
  • Over the past 3 years, Anika Therapeutics' median Current Deferred Revenue value was $2.2 million (recorded in 2013), while the average stood at $2.4 million.
  • In the last 5 years, Anika Therapeutics' Current Deferred Revenue spiked by 192.08% in 2011 and then tumbled by 98.90% in 2014.
  • Yearly analysis of 5 years shows Anika Therapeutics' Current Deferred Revenue stood at $2.7 million in 2010, then soared by 192.08% to $7.9 million in 2011, then crashed by 36.24% to $5.0 million in 2012, then slumped by 55.54% to $2.2 million in 2013, then slumped by 98.90% to $24,510 in 2014.